AlloCure Inc.
This article was originally published in Start Up
Executive Summary
There are precious few options for addressing acute kidney injury, a condition that is characterized by a rapid deterioration of kidney function, often occurring in people with certain risk factors and co-morbidities. Some 300,000 to 500,000 people each year in the US suffer from AKI. AlloCure Inc. is developing bone marrow-derived adult stem cells harvested from anonymous donors, and prepared as an off-the-shelf therapy, to prevent and perhaps eventually treat AKI.